Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights

Fineline Cube Apr 13, 2026
Company Deals

Merck KGaA Closes Acquisition of JSR Life Sciences’ Chromatography Business, Bolstering Antibody Purification Portfolio

Fineline Cube Apr 13, 2026
Company Deals Drug

Boehringer Ingelheim and BioNTech Launch Phase Ib/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC

Fineline Cube Apr 13, 2026
Company Deals

Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets

Fineline Cube Apr 13, 2026
Company Deals

Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology

Fineline Cube Apr 13, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

FDA Accepts NDA for Telix’s Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026

Fineline Cube Apr 13, 2026
Company Drug

GSK’s B7-H4 ADC Mocertatug Rezetecan Shows 62-67% Response Rates in Phase I Ovarian and Endometrial Cancer Trials

Fineline Cube Apr 13, 2026
Company Medical Device

Peijia Medical Commences Clinical Study for Taurus Trio TAVR System with First Patient Enrollment

Fineline Cube Aug 1, 2023

Peijia Medical Ltd (HKG: 9996) has announced the enrollment of the first patient in a...

Company Drug

RemeGen’s Novel Bispecific Antibody RC148 Receives Clinical Trial Approval

Fineline Cube Aug 1, 2023

China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has announced that it has received clinical trial...

Company R&D

Hainan Boao Lecheng Partners with BeiGene to Boost Medical Tourism and Biotech Innovation

Fineline Cube Aug 1, 2023

The Hainan Boao Lecheng International Medical Tourism Pilot Zone has entered into a partnership with...

Company Drug

Jiangsu Hengrui’s Camrelizumab and Apatinib Combo Accepted for FDA Review for HCC Treatment

Fineline Cube Aug 1, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that the US Food and Drug...

Company Drug

Jacobio Pharma’s Glecirasib Enters Breakthrough Therapy Review for Pancreatic Cancer Treatment

Fineline Cube Aug 1, 2023

China-based Jacobio Pharma (HKG: 1167) has announced that its novel KRAS G12C inhibitor, glecirasib, has...

Company Drug

Jiangsu Aidea’s ACC008 Demonstrates Non-Inferior Efficacy to Genvoya in Phase III HIV Study

Fineline Cube Aug 1, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced the summary report of a Phase...

Company Drug

Everest Medicines Completes Enrollment for Nefecon’s Phase III Extension Study in China

Fineline Cube Aug 1, 2023

China-based Everest Medicines (HKG: 1952) has announced the completion of patient enrollment for the China...

Company

WuXi AppTec Reports 6.28% Revenue Growth and 23.67% Net Profit Increase in H1 2023

Fineline Cube Aug 1, 2023

China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for...

Company

HutchMed Ltd Reports 164% Revenue Growth and Clinical Updates for H1 2023

Fineline Cube Aug 1, 2023

China-based HutchMed Ltd (NASDAQ: HCM; HKG: 0013) has announced its unaudited financial results for the...

Policy / Regulatory

Shanghai HSA Unveils Measures to Boost Access to Innovative Drugs and Devices

Fineline Cube Aug 1, 2023

The Healthcare Security Administration (HSA) in Shanghai has recently released a set of Measures aimed...

Company

Akeso Biopharma Reports First Positive Earnings in H1 2023 Financial Results

Fineline Cube Jul 31, 2023

Akeso Biopharma (HKG: 9926) has released its financial report for the first half of 2023,...

Company Medical Device

MicroPort MedBot’s SkyWalker Orthopedic Surgery Robot Gains TGA Approval in Australia

Fineline Cube Jul 31, 2023

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing...

Policy / Regulatory

CDE Releases Draft Guidelines for Clinical Pharmacology Research of Chemical Modified Drugs

Fineline Cube Jul 31, 2023

The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Clinical Pharmacological Research...

Company Deals

Baidu Health Partners with GSK for Shingles Disease Education Programs in China

Fineline Cube Jul 31, 2023

China Internet giant Baidu’s Health Internet Hospital unit has entered into a strategic partnership with...

Company Drug

Transcenta Holdings Gets CDE Approval for Phase II Study of TST002 for Bone Density

Fineline Cube Jul 31, 2023

China-based biotech company Transcenta Holdings Ltd (HKG: 6628) has announced that it has received approval...

Company Drug

Zelgen Biopharmaceuticals’ ZG006 Earns NMPA Approval for Clinical Trials in Solid Tumors

Fineline Cube Jul 31, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based biopharmaceutical company, has announced that it...

Company Deals

Mabwell Secures Licensing Deal with Morocco’s Sothema for Biosimilar Humira

Fineline Cube Jul 31, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a significant licensing and commercialization...

Company Drug

Shanghai Benemae’s Benaglutide Approved by NMPA for Adult Weight Management in China

Fineline Cube Jul 31, 2023

The National Medical Products Administration (NMPA) has indicated on its website that benaglutide, developed by...

Company Drug

Nanjing Leads Biolabs’ LBL-034 Secures Clinical Trial Approvals from NMPA and FDA

Fineline Cube Jul 31, 2023

Nanjing Leads Biolabs Co., Ltd, a China-based biopharmaceutical company, has announced receiving clinical trial approvals...

Company Deals

Sanofi to Boost CHC Unit with Full Acquisition of US Health Brand Qunol

Fineline Cube Jul 31, 2023

France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has revealed that it has signed an agreement to...

Posts pagination

1 … 478 479 480 … 649

Recent updates

  • Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights
  • FDA Accepts NDA for Telix’s Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026
  • GSK’s B7-H4 ADC Mocertatug Rezetecan Shows 62-67% Response Rates in Phase I Ovarian and Endometrial Cancer Trials
  • Merck KGaA Closes Acquisition of JSR Life Sciences’ Chromatography Business, Bolstering Antibody Purification Portfolio
  • Boehringer Ingelheim and BioNTech Launch Phase Ib/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights

Company Drug

FDA Accepts NDA for Telix’s Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026

Company Drug

GSK’s B7-H4 ADC Mocertatug Rezetecan Shows 62-67% Response Rates in Phase I Ovarian and Endometrial Cancer Trials

Company Deals

Merck KGaA Closes Acquisition of JSR Life Sciences’ Chromatography Business, Bolstering Antibody Purification Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.